API Manufacturing Violations Compounded By Repeat Offenses, Unapproved Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warning letters to two manufacturers of active pharmaceutical ingredients stress the need for validated procedures and fully detailed responses to inspectional observations.
You may also be interested in...
When Responding To A Warning Letter, Act Within 15 Days
When an FDA inspection of a drug manufacturing plant turns up potential violations that are noted on the official Form 483 report, the company should respond in complete detail within 15 days or risk having its response officially disregarded.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.